This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.
Perthera and PanCAN Publish Pivotal Paper in Lancet Oncology Highlighting the Importance of Selecting Treatments Based on Tumor Mutations
AI-enabled precision, speed and scale
Precision oncology and speed to decision, for everyone, at every point of care.
How We Help